Literature DB >> 4035298

Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma.

T E Mollnes, T Lea, M Harboe, J Tschopp.   

Abstract

The terminal complement complex (TCC), consisting of C5b, C6, C7, C8, and C9, contains neoantigens that are absent from the individual native components. Neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. The present study describes production of monoclonal antibodies against neoantigens of both forms of the TCC. A convenient screening and detection system, based mainly on enzyme-linked immunosorbent assays, crossed immunoelectrophoresis with autoradiography, and affinity chromatography with subsequent sodium dodecyl sulphate-polyacrylamide gel electrophoresis including immunoblotting, is described in detail. Two monoclonal antibodies were specific for a neoantigen located in the poly(C9) moiety of the TCC. One of these antibodies, MCaE11, was used for immunohistochemical detection of MAC in tissue and for quantification of the fluid-phase TCC in ethylenediaminetetraacetic acid plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4035298     DOI: 10.1111/j.1365-3083.1985.tb01870.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  57 in total

1.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes.

Authors:  Robert Graham Quinton Leslie; Claus Henrik Nielsen
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

3.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.

Authors:  R Würzner; H Xu; A Franzke; M Schulze; J H Peters; O Götze
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

5.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Adhesion molecule expression and complement activation in vessel walls in synovial tissue from patients with chronic inflammatory joint disease.

Authors:  O J Mellbye; Y Shen; K Høgåsen; T E Mollnes; O Førre
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

7.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon.

Authors:  T S Halstensen; T E Mollnes; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

8.  Sarcolemmal Complement Membrane Attack Complex Deposits During Acute Rejection of Myofibers in Nonhuman Primates.

Authors:  Daniel Skuk; Jacques P Tremblay
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

9.  Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae.

Authors:  F Tedesco; O Radillo; G Candussi; A Nazzaro; T E Mollnes; D Pecorari
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

10.  Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation.

Authors:  C M Verduin; M Jansze; C Hol; T E Mollnes; J Verhoef; H van Dijk
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.